Response of therapy‐associated acute nonlymphocytic leukemia to intensive induction chemotherapy

Steven F. Duane, Bruce A Peterson, Clara D. Bloomfield, Sheryl D. Michels, David D. Hurd

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Among 31 consecutive patients who developed acute nonlymphocytic leukemia following treatment with chemotherapy or radiation therapy, 17 were treated with intensive chemotherapy aimed at inducing a complete remission. Seven of these 17 patients (41%) obtained a complete remission that ranged in duration from 2 to 11 (median 3) months. Two additional patients who failed to develop normal peripheral blood counts despite postinduction bone marrows that were normocellular and free of leukemia were classified as nonresponders. The median time to complete remission and median duration of leukopenia (WBC < 1,000/μ1) were 34 days and 23 days, respectively. Induction chemotherapy was complicated by fever in all patients, documented infection in six patients, and death secondary to sepsis in three. Survival of the 17 patients ranged from <1 to 39 (median 4) months. Patients achieving a complete remission had a median survival time of 10 months compared to 2 months for the nonresponders. The other 14 patients received only supportive care and had a median survival of 2 months. These findings indicate that therapy‐associated acute nonlymphocytic leukemia (t‐ANLL) can frequently respond to chemotherapy and that achieving a complete remission is associated with longer survival. Although these results are encouraging, patients with t‐ANLL still have a relatively poor prognosis and efforts directed at improving treatment outcome need to be continued.

Original languageEnglish (US)
Pages (from-to)207-213
Number of pages7
JournalMedical and Pediatric Oncology
Volume13
Issue number4
DOIs
StatePublished - 1985

Keywords

  • therapy
  • treatment‐associated leukemia

Fingerprint Dive into the research topics of 'Response of therapy‐associated acute nonlymphocytic leukemia to intensive induction chemotherapy'. Together they form a unique fingerprint.

Cite this